Clinical trial · Interventional
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
NCT01477463CI-TRIAL-00025258completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the signaling pathways and changes in gene expression in melanocytes of subjects with a history of non-melanoma skin cancer who are exposed to oral vitamin D. If vitamin D is found to inhibit a signaling pathway involved in the development of melanoma such as BRAF, a protein involved in cell proliferation, then oral vitamin D could be explored further as a chemoprevention for melanoma skin cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma, Skin | Cutaneous Melanoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| placebo and vitamin D | Drug | — | UNRESOLVED |
| Vitamin D3 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm A: Vitamin D
- description
- 4,000 IU oral vitamin D3
- interventionNames
- Drug: Vitamin D3
- type
- EXPERIMENTAL
- label
- Arm B: Placebo + Vitamin D
- description
- Placebo + 4000 IU oral Vitamin D3
- interventionNames
- Drug: placebo and vitamin D
Primary outcomes (2)
- measure
- Number of Genes That Showed Changes in Expression After Vitamin D Treatment
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 - 75 2. Female 3. White race/ethnicity 4. With history of non-melanoma skin cancer 5. Has 12-16 moles upon skin examination 6. Consents to 6-12 moles biopsies over 2-3 clinic visits (2-4 months) 7. Consents to ingesting oral vitamin D3 or placebo daily for 2-4 months 8. Consents to abstaining from other multivitamins during study 9. Consents to research use of their tissue and blood samples 10. Agrees to apply a sunscreen of SPF 45 during study - Exclusion Criteria: 1. History or current evidence of hyperparathyroidism, hypercalcemia, renal calculi, or other renal disease. 2. History or current evidence of malabsorptive illnesses, such as IBD, or liver disease that would impair uptake or metabolism of vitamin D. 3. History or current evidence of hyperthyroidism that would increase metabolism of vitamin D. 4. History or current evidence of immunosuppression (cancer, autoimmune disease) or taking immunosuppressive drugs. 5. Currently taking medications that would affect metabolism of vitamin D (anticonvulsants, corticosteroids, H2-receptor antagonists). 6. Currently taking medications that predispose to hypercalcemia (digoxin, lithium, thiazide diuretics) or other electrolyte disturbances (aluminum hydroxide) 7. Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.